293 related articles for article (PubMed ID: 17034294)
21. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone.
Taveira-DaSilva AM; Stylianou MP; Hedin CJ; Hathaway O; Moss J
Chest; 2004 Dec; 126(6):1867-74. PubMed ID: 15596686
[TBL] [Abstract][Full Text] [Related]
22. Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis.
Kumasaka T; Seyama K; Mitani K; Sato T; Souma S; Kondo T; Hayashi S; Minami M; Uekusa T; Fukuchi Y; Suda K
Am J Surg Pathol; 2004 Aug; 28(8):1007-16. PubMed ID: 15252306
[TBL] [Abstract][Full Text] [Related]
23. The role of moesin in diagnosing and assessing severity of lymphangioleiomyomatosis.
Song X; Cai H; Peng W; Chen K; Abuduxukuer Z; Zeng Y; Zhu G; Lu C; Chen Y; Wang J; Ye L; Jin M
Respir Res; 2024 Jan; 25(1):57. PubMed ID: 38267973
[TBL] [Abstract][Full Text] [Related]
24. Involvement of lymphatics in lymphangioleiomyomatosis.
Glasgow CG; Taveira-DaSilva A; Pacheco-Rodriguez G; Steagall WK; Tsukada K; Cai X; El-Chemaly S; Moss J
Lymphat Res Biol; 2009 Dec; 7(4):221-8. PubMed ID: 20143921
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.
Atochina-Vasserman EN; Abramova E; James ML; Rue R; Liu AY; Ersumo NT; Guo CJ; Gow AJ; Krymskaya VP
Am J Physiol Lung Cell Mol Physiol; 2015 Dec; 309(12):L1447-54. PubMed ID: 26432869
[TBL] [Abstract][Full Text] [Related]
26. Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study.
Goldberg HJ; Harari S; Cottin V; Rosas IO; Peters E; Biswal S; Cheng Y; Khindri S; Kovarik JM; Ma S; McCormack FX; Henske EP
Eur Respir J; 2015 Sep; 46(3):783-94. PubMed ID: 26113676
[TBL] [Abstract][Full Text] [Related]
27. Effect of fasting on the size of lymphangioleiomyomas in patients with lymphangioleiomyomatosis.
Taveira-DaSilva AM; Jones AM; Julien-Williams P; Shawker T; Glasgow CG; Stylianou M; Moss J
Chest; 2015 Oct; 148(4):1027-1033. PubMed ID: 26066372
[TBL] [Abstract][Full Text] [Related]
28. Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis.
Chang WY; Cane JL; Blakey JD; Kumaran M; Pointon KS; Johnson SR
Respir Res; 2012 Apr; 13(1):34. PubMed ID: 22513045
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of Combined Resveratrol and Sirolimus in Lymphangioleiomyomatosis.
Gupta N; Zhang B; Zhou Y; McCormack FX; Ingledue R; Robbins N; Kopras EJ; McMahan S; Singla A; Swigris J; Cole AG; Holz MK
Chest; 2023 May; 163(5):1144-1155. PubMed ID: 36642366
[TBL] [Abstract][Full Text] [Related]
30. Role of serum vascular endothelial growth factor D in discrimination of patients with polycystic lung diseases.
Radzikowska E; Jaguś P; Skoczylas A; Sobiecka M; Chorostowska-Wynimko J; Wiatr E; Kuś J; Roszkowski-Śliż K
Pol Arch Med Wewn; 2013; 123(10):533-8. PubMed ID: 24060688
[TBL] [Abstract][Full Text] [Related]
31. Isolation and characterisation of lymphatic endothelial cells from lung tissues affected by lymphangioleiomyomatosis.
Nishino K; Yoshimatsu Y; Muramatsu T; Sekimoto Y; Mitani K; Kobayashi E; Okamoto S; Ebana H; Okada Y; Kurihara M; Suzuki K; Inazawa J; Takahashi K; Watabe T; Seyama K
Sci Rep; 2021 Apr; 11(1):8406. PubMed ID: 33863980
[TBL] [Abstract][Full Text] [Related]
32. Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis.
Crausman RS; Lynch DA; Mortenson RL; King TE; Irvin CG; Hale VA; Newell JD
Chest; 1996 Jan; 109(1):131-7. PubMed ID: 8549175
[TBL] [Abstract][Full Text] [Related]
33. Lymphangioleiomyomatosis: a disease involving the lymphatic system.
Seyama K; Kumasaka T; Kurihara M; Mitani K; Sato T
Lymphat Res Biol; 2010 Mar; 8(1):21-31. PubMed ID: 20235884
[TBL] [Abstract][Full Text] [Related]
34. Immunohistological features related to functional impairment in lymphangioleiomyomatosis.
Nascimento ECTD; Baldi BG; Mariani AW; Annoni R; Kairalla RA; Pimenta SP; da Silva LFF; Carvalho CRR; Dolhnikoff M
Respir Res; 2018 May; 19(1):83. PubMed ID: 29739412
[TBL] [Abstract][Full Text] [Related]
35. Lymphatic manifestations of lymphangioleiomyomatosis.
Gupta R; Kitaichi M; Inoue Y; Kotloff R; McCormack FX
Lymphology; 2014 Sep; 47(3):106-17. PubMed ID: 25420303
[TBL] [Abstract][Full Text] [Related]
36. Pulmonary function test results are correlated with 6-minute walk distance, distance-saturation product, and 6-minute walk work in patients with lymphangioleiomyomatosis.
Diesler R; Cottin V; Gallien Y; Turquier S; Traclet J; Ahmad K; Glerant JC
Respir Med Res; 2024 Jun; 85():101071. PubMed ID: 38141576
[TBL] [Abstract][Full Text] [Related]
37. Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyomatosis.
Lazor R; Valeyre D; Lacronique J; Wallaert B; Urban T; Cordier JF;
Respir Med; 2004 Jun; 98(6):536-41. PubMed ID: 15191039
[TBL] [Abstract][Full Text] [Related]
38. St. George's Respiratory Questionnaire has longitudinal construct validity in lymphangioleiomyomatosis.
Swigris JJ; Lee HS; Cohen M; Inoue Y; Moss J; Singer LG; Young LR; McCormack FX;
Chest; 2013 Jun; 143(6):1671-1678. PubMed ID: 23328755
[TBL] [Abstract][Full Text] [Related]
39. CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis.
Glasgow CG; Pacheco-Rodriguez G; Steagall WK; Haughey ME; Julien-Williams PA; Stylianou MP; Gochuico BR; Moss J
Chest; 2018 Feb; 153(2):339-348. PubMed ID: 28576630
[TBL] [Abstract][Full Text] [Related]
40. Determinants of Progression and Mortality in Lymphangioleiomyomatosis.
Xu W; Yang C; Cheng C; Wang Y; Hu D; Huang J; He Y; Wang J; Chen K; Yang L; Zhou W; Zhang T; Liu S; Dai J; Meng S; Li X; Yang Y; Wang ST; Feng R; Zhang W; Zhang H; Wang L; Tian X; Xu KF
Chest; 2023 Jul; 164(1):137-148. PubMed ID: 36801466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
